

**Supplementary Table 1.** Early treatment outcomes according to the intensity of the BHAC-based induction chemotherapy.

Total (N=752)	IDA/BHAC 3/7 (N=181)	IDA/BHAC 3/10 (N=287)	IDA/BHAC 5/10 (N=284)	P
Post-induction early death <sup>a)</sup> (N=38, 5.1%)	14 (7.7%)	10 (3.5%)	14 (4.9%)	0.123
≤ 55 yr (N=651)	9/137 (6.6%)	5/246 (2.0%)	11/268 (4.1%)	0.082
> 55 yr (N=101)	5/44 (11.4%)	5/41 (12.2%)	3/16 (18.8%)	0.741
Favorable-risk (N=176)	3/32 (9.4%)	1/55 (1.8%)	4/89 (4.5%)	0.264
Intermediate-risk (N=400)	7/104 (6.7%)	7/171 (4.1%)	4/125 (3.2%)	0.414
Adverse-risk (N=169)	4/43 (9.3%)	2/59 (3.4%)	6/67 (9.0%)	0.387
CR after induction CTx (N=537, 71.4%)	105 (58.0%)	219 (76.3%)	213 (75.0%)	<0.001 <sup>b)</sup>
≤ 55 yr (N=651)	84/137 (61.3%)	196/246 (79.7%)	205/268 (76.5%)	<0.001 <sup>b)</sup>
> 55 yr (N=101)	21/44 (47.7%)	23/41 (56.1%)	8/16 (50.0%)	0.736
Favorable-risk	27/32 (84.4%)	52/55 (94.5%)	82/89 (92.1%)	0.249
Intermediate-risk	58/104 (55.8%)	127/171 (74.3%)	90/125 (72.0%)	0.004 <sup>b)</sup>
Adverse-risk	20/43 (46.5%)	39/59 (66.1%)	41/67 (61.2%)	0.126
Final CR achievement (N=600, 79.8%)	123 (68.0%)	242 (84.3%)	235 (82.7%)	<0.001 <sup>b)</sup>
≤ 55 yr (N=651)	102/137 (74.5%)	214/246 (87.0%)	225/268 (84.0%)	0.006 <sup>b)</sup>
> 55 yr (N=101)	21/44 (47.7%)	28/41 (68.3%)	10/16 (62.5%)	0.148
Favorable-risk	29/32 (90.6%)	53/55 (96.4%)	84/89 (94.4%)	0.537
Intermediate-risk	72/104 (69.2%)	141/171 (82.5%)	103/125 (82.4%)	0.018 <sup>b)</sup>
Adverse-risk	22/43 (51.2%)	46/59 (78.0%)	47/67 (70.1%)	0.015 <sup>b)</sup>
Relapse before HCT (N=72, 13.2%)	23/123 (18.7%)	26/242 (10.7%)	23/235 (9.8%)	0.035 <sup>b)</sup>
≤ 55 yr	17/102 (16.6%)	21/214 (9.8%)	21/225 (9.3%)	0.115
> 55 yr	6/21 (28.6%)	5/28 (17.8%)	2/10 (20.0%)	0.660
Favorable-risk	2/29 (6.9%)	1/53 (1.9%)	3/84 (3.6%)	0.509
Intermediate-risk	16/72 (22.2%)	15/141 (10.6%)	12/103 (11.6%)	0.051
Adverse-risk	5/22 (22.7%)	9/46 (19.5%)	8/47 (17.0%)	0.850

<sup>a)</sup>Early death due to any cause (with or without aplasia) within 56 days after chemotherapy. <sup>b)</sup>P < 0.05. Abbreviations: CTx, chemotherapy; HCT, hematopoietic cell transplantation.

**Supplementary Table 2.** Early treatment outcomes according to the intensity of the cytarabine-based induction chemotherapy.

Total (N=443)	IDA/ARA 3/7 (N=283)	IDA/ARA 3/10 (N=76)	IDA/ARA 5/10 (N=84)	P
Post-induction early death <sup>a)</sup> (N=19, 4.3%)	7 (2.5%)	5 (6.6%)	7 (8.3%)	0.037 <sup>b)</sup>
≤ 55 yr (N=358)	5/215 (2.3%)	2/66 (3.0%)	5/77 (6.5%)	0.216
> 55 yr (N=85)	2/68 (2.9%)	3/10 (30.0%)	2/7 (28.6%)	0.002 <sup>b)</sup>
Favorable-risk (N=81)	1/43 (2.3%)	1/19 (5.3%)	1/19 (5.3%)	0.783
Intermediate-risk (N=242)	3/162 (1.9%)	0/33 (0.0%)	4/47 (8.5%)	0.032 <sup>b)</sup>
Adverse-risk (N=109)	2/69 (2.9%)	4/22 (18.2%)	2/18 (11.1%)	0.045 <sup>b)</sup>
CR after induction CTx (N=312, 70.4%)	194 (68.6%)	59 (77.6%)	59 (70.2%)	0.305
≤ 55 yr	145/215 (67.4%)	53/66 (80.3%)	54/77 (70.1%)	0.135
> 55 yr	49/68 (72.1%)	6/10 (60.0%)	5/7 (71.4%)	0.736
Favorable-risk	37/43 (86.0%)	18/19 (94.7%)	18/19 (94.7%)	0.425
Intermediate-risk	111/162 (68.5%)	27/33 (81.8%)	31/47 (66.0%)	0.257
Adverse-risk	40/69 (58.0%)	13/22 (59.1%)	10/18 (55.6%)	0.974
Final CR achievement (N=367, 82.8%)	241 (85.2%)	63 (82.9%)	63 (75.0%)	0.096
≤ 55 yr	183/215 (85.1%)	57/66 (86.4%)	58/77 (75.3%)	0.107
> 55 yr	58/68 (85.3%)	6/10 (60.0%)	5/7 (71.4%)	0.127
Favorable-risk	41/43 (95.3%)	18/19 (94.7%)	18/19 (94.7%)	0.992
Intermediate-risk	135/162 (83.3%)	28/33 (84.8%)	34/47 (72.3%)	0.201
Adverse-risk	59/69 (85.5%)	16/22 (72.7%)	11/18 (61.1%)	0.057
Relapse before HCT (N=79, 21.5%)	57/241 (23.6%)	10/63 (15.9%)	12/63 (19.0%)	0.356
≤ 55 yr	35/183 (19.1%)	8/57 (14.0%)	11/58 (18.9%)	0.672
> 55 yr	22/58 (37.9%)	2/6 (33.3%)	1/5 (20.0%)	0.717
Favorable-risk	9/41 (21.9%)	0/18 (0.0%)	2/18 (11.1%)	0.077
Intermediate-risk	26/135 (19.2%)	5/28 (17.8%)	5/34 (14.7%)	0.827
Adverse-risk	18/59 (30.5%)	5/16 (31.2%)	5/11 (45.4%)	0.619

<sup>a)</sup>Early death due to any cause (with or without aplasia) within 56 days after chemotherapy. <sup>b)</sup>P < 0.05. Abbreviations: CTx, chemotherapy; HCT, hematopoietic cell transplantation.